← Leaderboards
Patricia A Barditch-Crovo
Johns Hopkins University
$0
Attributed
$0
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 4
By mechanism
M01$0 · 4
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Justin C McArthur$21,339,205
- Charles W. Flexner$41,000,447
- Chris Beyrer$53,118,025
- Joseph B. Margolick$86,818,342
- Richard E Chaisson$50,014,616
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchClinical Trial Phase IAids TherapyDrug Screening /EvaluationHiv InfectionsAdenine AnalogHuman Therapy EvaluationPharmacokineticsAntiaids AgentAntiviral AgentsAidsReverse Transcriptase InhibitorsDosageDrug Adverse EffectDrug InteractionsNucleoside AnalogNucleotide AnalogProdrugs
Grant awards (12)
TRIAL OF PHARMACOKINETICS OF PMPA PRODRUG IN HIV$0
M01 · FY2002 · RR
PHASE I/II ANTIVIRAL ACTIVITY OF 9R2, PROPYLADENINE (PMPA) IN HIV INFECTION$0
M01 · FY2002 · RR
PLACEBO CONTROLLED STUDY OF SAFETY OF PMPA IN HIV+ PATIENTS$0
M01 · FY2002 · RR
ANTIHIV ACTIVITY OF 60MG DAILY DOSE ADEFOVIR DIFIVOXIL IN HIV INFECTED PATIENTS$0
M01 · FY2002 · RR
PLACEBO CONTROLLED STUDY OF SAFETY OF PMPA IN HIV+ PATIENTS$0
M01 · FY2001 · RR
ANTIHIV ACTIVITY OF 60MG DAILY DOSE ADEFOVIR DIFIVOXIL IN HIV INFECTED PATIENTS$0
M01 · FY2001 · RR
TRIAL OF PHARMACOKINETICS OF PMPA PRODRUG IN HIV$0
M01 · FY2001 · RR
PHASE I/II ANTIVIRAL ACTIVITY OF 9R2, PROPYLADENINE (PMPA) IN HIV INFECTION$0
M01 · FY2001 · RR
PHASE I/II ANTIVIRAL ACTIVITY OF 9R2, PROPYLADENINE (PMPA) IN HIV INFECTION$0
M01 · FY2000 · RR
PLACEBO CONTROLLED STUDY OF SAFETY OF PMPA IN HIV+ PATIENTS$0
M01 · FY2000 · RR
ANTIHIV ACTIVITY OF 60MG DAILY DOSE ADEFOVIR DIFIVOXIL IN HIV INFECTED PATIENTS$0
M01 · FY2000 · RR
TRIAL OF PHARMACOKINETICS OF PMPA PRODRUG IN HIV$0
M01 · FY2000 · RR